Understanding the Tip:
Why testing photostability is essential regardless of packaging appearance:
Many stability programs bypass photostability testing if the product is stored in foil or opaque packaging. However, visual appearance is not a scientific measure of light protection. Even foil or opaque materials may allow trace light transmission, degrade over time, or show microdefects that let UV/visible light reach the product.
Photostability testing under ICH Q1B is crucial to determine the real light sensitivity of the drug product and validate whether the packaging performs as expected under stress.
Consequences of assuming protection without testing:
Skipping photostability testing can lead to unanticipated degradation, discoloration, potency loss, or even formation of toxic impurities. If degradation occurs during storage or patient use, it can trigger recalls, inspection findings, or patient safety concerns. Regulatory authorities may also reject data or request additional testing if photostability isn’t scientifically justified.
Examples of overlooked risk despite opaque materials:
Several products stored in foil-backed blisters or dark bottles have failed photostability due to minor perforations, adhesive layer degradation, or secondary exposure during dispensing. Without initial photostability testing, such risks go undetected until it’s too late.
Regulatory and Technical Context:
ICH Q1B guidance on photostability requirements:
ICH Q1B mandates photostability studies for all new drug substances and products,
The guideline recommends testing both in protective and light-transmitting packaging, and discourages assumptions based on packaging color or structure alone.
Regulatory expectations and submission standards:
Agencies like the FDA, EMA, and TGA require photostability data in Module 3.2.P.8.3 of the CTD. Even if the product is in foil or light-resistant packaging, regulators expect that this claim is backed by exposure data. Auditors also verify whether secondary packaging was tested under real-use conditions.
Best Practices and Implementation:
Always include photostability testing in protocol design:
Define a photostability arm in your stability protocol using ICH Q1B-recommended light exposure. Include both unprotected and fully packaged samples. Even for opaque packaging, test the worst-case exposure scenario—such as transparent unit-dose or opened packaging simulation.
Ensure samples are labeled and stored to avoid confusion, and document both visual and chemical degradation over time.
Evaluate real packaging performance, not assumptions:
Use UV-visible spectrophotometry or light transmittance tests to measure actual light-blocking properties of the packaging. Check for microdefects, edge sealing quality, and potential label-transmitted light exposure. Use comparative photostability profiles to determine if the packaging provides sufficient barrier under ICH stress.
Where degradation is observed, consider improving packaging design or adding protective overwraps.
Link photostability results to labeling and product protection:
Photostability results justify the need for protective labeling statements such as “Protect from light” or “Store in original packaging.” Incorporate findings into product development, packaging SOPs, and regulatory submission summaries. If testing confirms light sensitivity, ensure packaging and storage instructions reflect the risk.
Maintain photostability reports in your stability file and reference them during audits, shelf-life extensions, or packaging change assessments.